-
1.发明授权Implant having three-dimensional shape for electrically stimulating a nerve structure 有权植入物具有用于电刺激神经结构的三维形状公开(公告)号：US08774938B2
公开(公告)日：2014-07-08
申请号：US13695097
申请日：2011-04-29
申请人： Henri Lorach , Milan Djilas , Blaise Yvert , Philippe Bergonzo , Gaelle Lissorgues , Lionel Rousseau , Ryad Benjamin Benosman , Serge Picaud , Jose Sahel , Siohoi Ieng
发明人： Henri Lorach , Milan Djilas , Blaise Yvert , Philippe Bergonzo , Gaelle Lissorgues , Lionel Rousseau , Ryad Benjamin Benosman , Serge Picaud , Jose Sahel , Siohoi Ieng
IPC分类号： A61N1/00
CPC分类号： A61N1/0553 , A61N1/025 , A61N1/05 , A61N1/37205
摘要： The invention relates to an implant which includes, in order to electrically stimulate a nerve structure, in particular the retina, an electrically insulating substrate (1), a array of recesses (2) formed in an upper surface of the substrate, stimulation electrodes (3) arranged at the bottom of the recesses, and an electrically conductive layer forming a ground plane (4) at the upper portion of the recesses. The sizes of the recesses and of the electrodes of the implant are such that the spatial selectivity of the stimulation current applied to the nerve structure is maximized.
摘要翻译： 本发明涉及一种植入物，其包括为了电刺激神经结构，特别是视网膜，电绝缘基底（1），形成在基底上表面的凹槽阵列（2），刺激电极 3）布置在凹部的底部，以及在凹部的上部形成接地平面（4）的导电层。 植入物的凹部和电极的尺寸使得施加到神经结构的刺激电流的空间选择性最大化。
-
2.发明申请IMPLANT HAVING THREE-DIMENSIONAL SHAPE FOR ELECTRICALLY STIMULATING A NERVE STRUCTURE 有权具有三维形状的植入物用于电刺激神经结构公开(公告)号：US20130096660A1
公开(公告)日：2013-04-18
申请号：US13695097
申请日：2011-04-29
申请人： Henri Lorach , Milan Djilas , Blaise Yvert , Philippe Bergonzo , Gaelle Lissorgues , Lionel Rousseau , Ryad Benjamin Benosman , Serge Picaud , Jose Sahel , Siohoi Ieng
发明人： Henri Lorach , Milan Djilas , Blaise Yvert , Philippe Bergonzo , Gaelle Lissorgues , Lionel Rousseau , Ryad Benjamin Benosman , Serge Picaud , Jose Sahel , Siohoi Ieng
IPC分类号： A61N1/05
CPC分类号： A61N1/0553 , A61N1/025 , A61N1/05 , A61N1/37205
摘要： The invention relates to an implant which includes, in order to electrically stimulate a nerve structure, in particular the retina, an electrically insulating substrate (1), a array of recesses (2) formed in an upper surface of the substrate, stimulation electrodes (3) arranged at the bottom of the recesses, and an electrically conductive layer forming a ground plane (4) at the upper portion of the recesses. The sizes of the recesses and of the electrodes of the implant are such that the spatial selectivity of the stimulation current applied to the nerve structure is maximized
摘要翻译： 本发明涉及一种植入物，其包括为了电刺激神经结构，特别是视网膜，电绝缘基底（1），形成在基底上表面的凹槽阵列（2），刺激电极 3）布置在凹部的底部，以及在凹部的上部形成接地平面（4）的导电层。 植入物的凹部和电极的尺寸使得施加到神经结构的刺激电流的空间选择性最大化
-
公开(公告)号：US06716835B1
公开(公告)日：2004-04-06
申请号：US09806577
申请日：2001-06-08
申请人： Serge Picaud , Maria Frasson , Jose Sahel , Henri Dreyfus
发明人： Serge Picaud , Maria Frasson , Jose Sahel , Henri Dreyfus
IPC分类号： A61K3155
CPC分类号： A61K31/554 , A61K31/00 , Y10S514/912
摘要： The invention concerns the use of a calcium channel blocker compound and/or cyclic GMP-dependent channels, namely diltiazem, for treating retinal pathologies, and more particularly retinal diseases caused by degeneration of visual receptors, in a human or animal.
摘要翻译： 本发明涉及钙通道阻断剂化合物和/或环状GMP依赖性通道（即地尔硫卓）用于治疗视网膜病变，更特别是由人或动物视觉受体变性引起的视网膜疾病。
-
公开(公告)号：US20100062987A1
公开(公告)日：2010-03-11
申请号：US12515792
申请日：2007-11-22
申请人： Serge Picaud , Jose Sahel , Qinping Wang , Agnes Duboc , Manuel Simonutti
发明人： Serge Picaud , Jose Sahel , Qinping Wang , Agnes Duboc , Manuel Simonutti
IPC分类号： A61K38/05 , A61K31/195 , A61P25/08
摘要： The present invention pertains to pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one glutamate receptor activating substance.
摘要翻译： 本发明涉及药物组合物，其包含作为活性成分的活力蛋白和至少一种谷氨酸受体活化物质的组合。
-
公开(公告)号：US20090292021A1
公开(公告)日：2009-11-26
申请号：US12375970
申请日：2007-07-31
申请人： Serge Picaud , Agnes Duboc , Michel Paques , Jose Sahel , Manuel Simonutti
发明人： Serge Picaud , Agnes Duboc , Michel Paques , Jose Sahel , Manuel Simonutti
IPC分类号： A61K31/197 , A61P25/08
CPC分类号： A61K31/197 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one substance having anti-ischemic effect, are disclosed.
摘要翻译： 公开了包含作为活性成分的肌动蛋白和至少一种具有抗缺血作用的物质的组合的药物组合物。
-
公开(公告)号：US20100184707A1
公开(公告)日：2010-07-22
申请号：US12667742
申请日：2008-07-04
IPC分类号： A61K31/197 , A61K31/7076 , A61K38/06 , A61K31/549 , A61K31/445 , A61K31/66 , A61K31/47 , A61K31/496 , A61K31/4535 , A61K31/357 , A61K31/27 , A61K31/55 , A61K31/4985 , A61K31/519 , A61K31/437 , A61K31/4164
CPC分类号： A61K31/197 , A61K31/145 , A61K31/185 , A61K31/675 , A61K45/06 , A61K2300/00
摘要： The use of a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for manufacturing a pharmaceutical composition for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation.
摘要翻译： 使用选自牛磺酸，牛磺酸前体，牛磺酸代谢物，牛磺酸衍生物，牛磺酸类似物和牛磺酸生物合成所需的物质的物质，用于制备用于预防或抑制不期望的副作用的药物组合物， 通过诱导高水平的细胞外GABA或增加GABA受体活化的活性成分对人或动物生物体产生的作用。
-
公开(公告)号：US20120196281A1
公开(公告)日：2012-08-02
申请号：US13498619
申请日：2010-09-28
申请人： Volker Busskamp , Jens Duebel , Serge Picaud , Botond Roska , José Alain Sahel
发明人： Volker Busskamp , Jens Duebel , Serge Picaud , Botond Roska , José Alain Sahel
CPC分类号： C12N5/062 , C12N5/0697 , C12N2502/085 , C12N2502/99 , C12N2503/04 , C12N2510/00 , G01N33/5082 , G01N2500/10 , G01N2800/164
摘要： The present invention provides an organotypic system comprising a portion of a retina containing live cells in a cultured in medium, wherein photosensitivity has been restored in at least some of said live cells. Methods of use thereof are also provided.
摘要翻译： 本发明提供了包含在培养基中含有活细胞的视网膜的一部分的器官型系统，其中在至少一些所述活细胞中已恢复光敏性。 还提供了其使用方法。
-
8.发明申请Isolation and Culture of a High Purity Population of Cone Photoreceptor Cells by Tissue Dissociation and Pna-Panning, and Biological Applications Thereof 审中-公开通过组织解离和Pna淘选的锥形光感受器细胞的高纯度群体的分离和培养及其生物应用公开(公告)号：US20080280318A1
公开(公告)日：2008-11-13
申请号：US11587123
申请日：2005-04-22
申请人： Elise Balse , Luc-Henri Te ssier , Celine Fuchs , Valerie Forster , Jose-Alain Sahel , Serge Picaud
发明人： Elise Balse , Luc-Henri Te ssier , Celine Fuchs , Valerie Forster , Jose-Alain Sahel , Serge Picaud
CPC分类号： C12N5/062 , C12N2502/08 , C12N2503/02 , C12N2509/00
摘要： The present invention provides a process and kit for isolating cone photoreceptor cells from retinal tissue with a purity level of at least 80%, typically of about 90%. The isolation process uses a PNA-panning procedure conducted on dissociated retinal tissue. The present invention also provides a culture medium enabling the in vitro survival and development of such isolated cone cells. The means of the invention are applicable to adult mammalian cone cells, and more particularly to adult human cone cells. They have the advantage of being applicable to pathologic or otherwise altered cone cells, and thus give access to the screening of compounds capable of showing neuroprotective activity on adult cone cells.
摘要翻译： 本发明提供了用于从视网膜组织分离锥形感光细胞的方法和试剂盒，其纯度至少为80％，通常为约90％。 分离过程使用对解离的视网膜组织进行的PNA平移过程。 本发明还提供能够使这种分离的锥细胞的体外存活和发育的培养基。 本发明的方法适用于成年哺乳动物锥形细胞，更具体地涉及成年人锥形细胞。 它们具有适用于病理或其它改变的锥形细胞的优点，并且因此使得能够筛选能够对成体锥细胞显示神经保护活性的化合物进行筛选。
-
公开(公告)号：US08603964B2
公开(公告)日：2013-12-10
申请号：US13002395
申请日：2009-07-03
申请人： Romain Bernard , Bénédicte Dupas , Alain Gaudric , Serge Picaud , Alvaro Rendon , José-Alain Sahel , Abdoulaye Sene , Florian Sennlaub , Ramin Tadayoni , Eric Vicaut
发明人： Romain Bernard , Bénédicte Dupas , Alain Gaudric , Serge Picaud , Alvaro Rendon , José-Alain Sahel , Abdoulaye Sene , Florian Sennlaub , Ramin Tadayoni , Eric Vicaut
CPC分类号： A61K31/352 , A61K31/00 , A61K31/711 , A61K38/1709
摘要： The present invention relates to methods and compositions for inhibiting or stimulating angiogenesis. The invention shows the implication of Dp71 in angiogenesis and thus provides novel therapeutic approaches, as well as novel methods for screening agents modulating angiogenesis, which target this protein. More specifically, the present invention relates to the use of Dp71 or a variant thereof (or a coding nucleic acid) for stimulating angiogenesis in a subject, particularly a human subject. The invention relates to the use of an inhibitor of Dp71 for inhibiting angiogenesis in a subject.
摘要翻译： 本发明涉及抑制或刺激血管发生的方法和组合物。 本发明显示了Dp71在血管发生中的意义，因此提供了新的治疗方法，以及用于调节靶向该蛋白质的血管生成的筛选剂的新方法。 更具体地，本发明涉及用于刺激受试者，特别是人受试者的血管生成的Dp71或其变体（或编码核酸）的用途。 本发明涉及Dp71抑制剂在受试者中抑制血管发生的用途。
-
10.发明申请TAURINE OR TAURINE-LIKE SUBSTANCES FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION 审中-公开用于预防和治疗与恶性肿瘤细胞变性相关的疾病的TAURINE或TAURINE-LIKE物质公开(公告)号：US20120027723A1
公开(公告)日：2012-02-02
申请号：US13190812
申请日：2011-07-26
申请人： Serge Picaud
发明人： Serge Picaud
IPC分类号： A61K38/21 , A61K31/7076 , A61K38/06 , A61K31/205 , A61K31/145 , A61K31/445 , A61K31/541 , A61K31/496 , A61K31/66 , A61K31/195 , A61K31/47 , A61K31/155 , A61K31/4415 , A61K31/714 , A61K31/519 , A61K31/525 , A61K31/455 , A61K31/51 , A61K31/197 , A61K31/7048 , A61K31/5377 , A61K33/24 , A61K31/5415 , A61P25/00 , A61P27/02 , A61K31/198
CPC分类号： A61K31/185 , A61K31/00 , A61K31/155 , A61K31/195 , A61K31/197 , A61K31/198 , A61K31/205 , A61K31/4415 , A61K31/4462 , A61K31/455 , A61K31/4985 , A61K31/51 , A61K31/519 , A61K31/525 , A61K31/585 , A61K31/662 , A61K31/7076 , A61K31/714 , A61K38/063 , A61K38/13 , A61K45/06 , Y02A50/401 , Y02A50/411 , A61K2300/00
摘要： The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention and treatment of a disease associated with retinal ganglion cell degeneration.
摘要翻译： 本发明涉及用于预防和治疗与视网膜神经节细胞变性相关的疾病的牛磺酸或牛磺酸样物质。 更具体地，本发明涉及选自牛磺酸，牛磺酸前体，牛磺酸代谢物，牛磺酸衍生物，牛磺酸类似物和用于预防和治疗与视网膜相关的疾病的牛磺酸生物合成所需的物质的物质 神经节细胞变性。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.029 秒)
